Physician profile
Scott A Gartner
NPI 1144334103
$1,465.35
in general payments reported to CMS, 2019-2025
11 companies · $49.46 in 2025
The $49.46 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $142 · 2021: $112 · 2022: $253 · 2023: $368 · 2024: $138 · 2025: $49.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $328.59 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $242.94 | 2023 | Miebo |
| Apellis Pharmaceuticals, INC. | $170.78 | 2023-2024 | Syfovre |
| Johnson & Johnson Vision Care, INC. | $131.61 | 2022 | |
| Horizon Therapeutics Plc | $120.89 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $111.86 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $111.10 | 2019 | |
| Alcon Vision LLC | $92.51 | 2024 | Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.07 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $49.46 | 2025 | Xdemvy |
| Optos, INC. | $36.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.